Heart failure (HF) is the terminal consequence of many cardiac disorders, and the incidence of HF is expected to increase exponentially in the future.
INTRODUCTION
Heart failure (HF) is the terminal consequence of many cardiac disorders, and the incidence of HF is expected to increase exponentially in the future. (1) Although there are available pharmacotherapies that improve the mortality and morbidity of HF, (2) (3) (4) (5) these pharmacotherapies are often underutilised or prescribed at suboptimal doses. (6, 7) To address this shortcoming, many developed countries have initiated and established specialised HF clinics that are managed by a multidisciplinary team comprising physicians, pharmacists and various paramedical staff. Pharmacist-recommended optimisation of angiotensin-converting enzyme (ACE) inhibitor therapy has been shown to result in fewer hospitalisations and lower treatment costs. (8) (9) (10) When pharmacists initiated and up-titrated anti-failure medications under the supervision of a cardiologist, the prescription rates of ACE inhibitors, beta-blockers and spironolactone increased, with improvements in the symptoms and functional class of patients (i.e. reductions in heart rate and systolic blood pressure without adverse renal effects). (11) In Malaysia, specialised HF clinics are not available in all government and private hospitals. Thus, many patients with HF are managed at a primary and secondary care level, often by junior medical staff. In such cases, pharmacist involvement in HF patient care can be enhanced through the use of standardised evidencebased treatment protocols. Hence, the primary objective of this study was to develop HF treatment algorithms and monitoring protocols and to validate them using an adapted Delphi method.
METHODS
Randomised controlled trials, meta-analyses and review articles on HF management and guidelines, which were published between January 1998 and December 2012, were identified using PubMed, OvidSP, SpringerLink, ScienceDirect and EBSCOhost. Using predefined search criteria, a total of 3,142 articles were identified. Of the 320 articles subsequently selected for full-text reading, 212 articles were deemed beneficial to this study. The evidence-based data obtained from this literature review was used to develop detailed guidance on initiating, titrating and monitoring ACE inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers and spironolactone.
The treatment protocols were then validated using an adapted Delphi survey. The Delphi survey technique was used to generate discussion among a panel of experts and to eventually obtain a consensus of opinion regarding HF management. This technique enables information and opinions to be collected in a neutral environment. (12) Since information and opinions were gathered via several rounds of structured questionnaires, face-to-face meeting of the panellists was avoided. This maintains the anonymity of the responses and prevents monopolisation of any particular opinion. In this study, two rounds of surveys were conducted on the panel of experts. The responses of the panellists were tallied and amendments were made before the protocols were ready to be used.
To recruit the panel of experts for the present study, we invited 40 doctors and pharmacists from local private, institutional Development and validation of algorithms for heart failure patient care: a Delphi study and government hospitals via email and telephone. Of these 40 doctors and pharmacists, 32 agreed to participate in the study; the remaining 8 declined due to work commitments or without reason. The final panel consisted of 12 cardiologists, 10 physicians and 10 pharmacists. Among the 32 panellists, half were women. On average, the pharmacists were about ten years younger than the cardiologists and physicians. Most of the panellists (71.9%) had over ten years of clinical experience, and at least half of the patients they managed monthly were patients with HF.
The panellists were required to complete a self-administered questionnaire, which aimed to determine their level of agreement with the ACE inhibitor, ARB, beta-blocker and spironolactone treatment protocols in relation to the following areas: (a) contraindications and cautions to initiating drug therapy; (b) individual and overall components of initiation and titration algorithms; (c) monitoring parameters and frequency of monitoring; (d) recommended approaches to dealing with commonly encountered treatment-related problems; (e) information to be provided to patients; and (f) clinically significant interactions between the four agents and commonly co-administered drugs. The level of agreement was measured using a Likert scale (1) (2) (3) (4) (5) (6) (7) (8) (9) . A score of 1, 2, 3 or 4 indicated varying degrees of disagreement with the statement/question -1 indicated the highest level of disagreement and 4, the lowest level of disagreement. A score of 6, 7, 8 or 9 indicated varying degrees of agreement -6 indicated the lowest level of agreement and 9, the highest level of agreement. A score of 5 represented a neutral opinion. The panellists were also encouraged to provide constructive comments.
The survey questionnaires were emailed (n = 4), posted (n = 3) or hand-delivered (n = 25). In the first round, the panel of experts received a formal letter of invitation, a study information sheet, the survey questionnaire and a self-addressed return envelope (if applicable). Confirmation of receipt of the questionnaires was done three days after mailing via telephone and email. A telephone reminder and a one-week extension were given for panellists who did not return the questionnaires on the due date, in view of their busy work schedules. Once all completed questionnaires were received, the responses were collated and tallied. Questions that achieved a group consensus were not presented for discussion in the second round, while questions that did not achieve a group consensus in the first round were re-presented in the second round, but only to the panellists whose responses were outside the majority opinion. Amendments to treatment protocols were made according to the suggestions of the panellists, prior to the second survey. The entire process of the Delphi method used in the present study is illustrated in Fig. 1 .
Data collected were entered and tabulated using Microsoft Excel (Microsoft Corp, Redmond, WA, USA). Descriptive statistics were generated for each designated Delphi question to determine whether a consensus had been achieved. A 'consensus of opinion' was defined as ≥ 70% agreement among the panellists; a 'majority opinion' was defined as 51%-69% agreement among the panellists, while a 'minority opinion' was defined as ≤ 50% agreement among the panellists. (13, 14) 
RESULTS
The panellists reached a consensus for all questions relating to: (a) contraindications to the commencement of the four agents (i.e. ACE inhibitors, ARBs, beta-blockers and spironolactone); and (b) cautions for initiating three of the four drugs in patients with HF (only a majority opinion was achieved for two of the five cautions for initiating beta-blocker therapy). With regard to the cautions for initiating beta-blocker therapy, 10 (31.3%) of the panellists disagreed on commencing beta-blockers among patients with hepatic and renal diseases. One panellist reasoned that this was because the statement was vague. Upon further explanation, seven of the ten panellists who initially disagreed joined the majority opinion, allowing a consensus to be achieved. There were also differing opinions (11 disagreed, 1 neutral) about the initiation of beta-blockers in patients with diabetes mellitus, as there was concern that such treatment would mask hypoglycaemic symptoms. After this statement was reworded, without compromising its integrity, a consensus was achieved in the second survey.
With regard to the individual drug algorithms, two sections of the ACE inhibitor and ARB treatment algorithms achieved a majority opinion, while the other sections achieved consensus. All the physicians (n = 10) surveyed indicated that they were not satisfied with the titration algorithms for ACE inhibitors (Fig. 2) and ARBs (Fig. 3) , in cases where serum creatinine levels increased by 30% to < 50% and 50% to < 100%. This portion was deemed too complicated for pharmacists to use, and drug cessation was considered necessary and warranted once serum creatinine level increased by more than 30% from the baseline. As all the physicians (n = 10) were not agreeable to this portion of the algorithm, this component of the titration protocol was amended to achieve consensus in the second survey. First-round consensus was achieved for the individual titration algorithms for beta-blockers and spironolactone (Figs. 4 & 5) .
In the third section of the questionnaire, which covered monitoring parameters and frequency, only 62.5% agreed (i.e. a majority opinion) with monitoring of electrolytes and renal function when using beta-blockers. A similar result was found for all but one of the parameters relating to information to be provided to the patient and clinically significant drug interactions with commonly used HF medications. When assessing the 'troubleshooting' section of the protocols, consensus was achieved among the panellists with regard to the suggested methods to deal with problems related to treatment with ACE inhibitors, ARBs, beta-blockers and spironolactone.
DISCUSSION
The present study showed that there were some concerns regarding the definitions of renal and hepatic failure when beta-blocker therapy is being considered for patients with HF. Post hoc analyses revealed that the addition of beta-blockers to standard HF therapy for patients with moderate to severe renal impairment (i.e. serum creatinine > 300 μmol/L) was found to reduce all-cause mortality in the Cardiac Insufficiency Bisoprolol Study II, (15) while for patients with worse renal function (estimated glomerular filtration rate < 45 mL/min/m 2 using the Modification of Diet in Renal Disease formula), greater mortality benefits (hazard ratio 0.41) were noted in the Metoprolol CR/XL Randomized Intervention Trial in Chronic HF. (16) Mortality and HF admissions were also found to be significantly reduced in a small study that used carvedilol in patients with dilated cardiomyopathy on regular haemodialysis. (17) As renal impairment is an independent predictor of negative outcomes in HF and beta-blocker therapy is beneficial in HF, it was concluded that patients at all levels of renal impairment would benefit from beta-blocker therapy, although clinicians should exercise caution. (15) (16) (17) With respect to liver impairment, metoprolol and carvedilol undergo extensive first-pass metabolism, whereas bisoprolol is excreted equally via the kidneys and liver. (18) Carvedilol elimination is significantly prolonged in patients with moderate to severe liver cirrhosis, warranting a two-to threefold reduction of the drug dose. (19) In view of this, beta-blockers can be utilised in patients with liver and renal impairment, albeit cautiously. A point of contention for all the physicians in the present study was the renal parameter cut-off levels for referral and uptitration of ACE inhibitors and ARBs. The cardiologists in the present study were comfortable with close monitoring instead of drug cessation in patients whose serum creatinine level rose more than 30% from baseline. In a study conducted by Bakris et al, the commencement of ACE inhibitors and ARBs in patients with pre-existing renal impairment (serum creatinine ≥ 124 μmol/L) reduced the progression of renal disease by 55%-75%. (20) Although the serum creatinine levels of the patients in that study were up to 30% higher than the baseline, the levels then stabilised within two months of drug initiation. (20) On the other hand, physicians were been found to be generally more conservative, and thus, 1.1-2.5 times less likely to prescribe ACE inhibitors than cardiologists. (21) Cardiologists were found to be more likely to prescribe higher doses of ACE inhibitors and less likely to preclude its use in patients with renal impairment (i.e. serum creatinine > 2.5 mg/dL or 221 μmol/L). (22) Physicians with more recent training were shown to have practice patterns that were more similar to those of cardiologists, as compared to physicians with more distant training. (22) The comments made by the physicians in the present study may be reflective of the aforementioned finding, as the majority of them (> 80%) had worked for more than ten years.
As the protocols developed in our study are intended for the use of pharmacists, who possibly have less clinical experience than our panellists and who are situated in centres with few or no physicians/Family Medicine Specialist (FMS), minor changes were made to the ACE inhibitor and ARB titration protocols, such that early referral to a cardiologist/physician/FMS is encouraged when serum creatinine level rises above 30% from the baseline. Review of concomitant nephrotoxic drugs and close biochemical monitoring, with or without cessation of ACE inhibitors and ARBs, are advised when creatinine level rises by 50% to < 100% and when delayed specialist review was anticipated.
In the present study, all the physicians (n = 10) and two of the cardiologists felt that monitoring renal function was not necessary when titrating beta-blockers. This parameter was included, as it was one of the expert recommendations listed in the National Institute for Health and Clinical Excellence guidelines on chronic HF management.
(23) Beta-blockers may transiently worsen HF symptoms, and consequently worsen renal function before beneficial effects are seen. Although carvedilol mainly undergoes hepatic metabolism, plasma levels will be elevated in patients with renal failure. For these reasons, it was deemed necessary to monitor renal parameters following the initiation and final titration of the agent.
One of the limitations of the present study is that all of the panellists were selected locally. This was done because the protocols were developed for use and local panellists would be most familiar with clinical practices and pharmacotherapies in Malaysia. Taking this into consideration, this 'limitation' may in fact be considered a strength of the present study (since the sampled panellists would best reflect the local management views and practices). Furthermore, as the titration protocols were developed based on international guidelines, it allowed for the exclusion of international panellists. In fact, based on the panellists' consensus, the final titration protocols were quite similar to those of various international guidelines. One other limitation was the absence of a face-to-face meeting among the panellists. A face-to-face meeting may have been beneficial for clarifying and working out any issues found within the titration protocols prior to their implementation. However, due to the panellists' hectic schedules and the study design, such a meeting was not possible.
In conclusion, the present Delphi study consulted a panel of experts, comprising cardiologists, physicians and pharmacists. The panel was able to achieve a consensus, which resulted in a set of validated drug titration protocols for the use of ACE inhibitors, ARBs, beta-blockers and spironolactone in patients with HF. These protocols can be used as a guide for pharmacists who need to initiate and titrate HF drug therapy in daily clinical practice. The recommendations of the pharmacists should be made in collaboration with the treating clinician.
